Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 8:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–89 of 89 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: UCB Biopharma SRL Clear all

Conditions: SLC6A1 Neurodevelopmental Disorder (NDD), Developmental and Epileptic Encephalopathies (DEE)
Interventions: Not listed
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: Up to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Participants
Interventions: Rozanolixizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Generalized Myasthenia Gravis
Interventions: zilucoplan (RA101495); Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Scottsdale, Arizona • Los Angeles, California • Rancho Mirage, California + 9 more

Conditions: Moderate to Severe Plaque Psoriasis
Interventions: bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Indianapolis, Indiana • Cypress, Texas

Conditions: Healthy Participants
Interventions: Zilucoplan; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 1,353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 48
States / cities: Glendale, Arizona • Phoenix, Arizona • Bakersfield, California + 43 more

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 11
States / cities: Lexington, Kentucky • Hagerstown, Maryland • Lansing, Michigan + 8 more

Conditions: Chronic Plaque Psoriasis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Bexley, Ohio

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions: Bimekizumab, Ustekinumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 25
States / cities: Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more

Conditions: Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions: Padsevonil, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 32
States / cities: Chandler, Arizona • Tucson, Arizona • Carlsbad, California + 29 more

Conditions: Generalized Myasthenia Gravis
Interventions: Rozanolixizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Orange, California • San Francisco, California • Miami, Florida + 9 more

Conditions: Ankylosing Spondylitis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: Sarasota, Florida • Duncansville, Pennsylvania • Dallas, Texas

Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions: Brivaracetam Film-coated tablet, Brivaracetam oral solution; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 2 Years to 26 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Birmingham, Alabama • Orange, California • Augusta, Georgia + 2 more

Conditions: Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: Glendale, Arizona • Phoenix, Arizona • Upland, California + 7 more

Conditions: Healthy Study Participants, Participants With Mild Asthma
Interventions: Alprazolam, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: North Dartmouth, Massachusetts • Raleigh, North Carolina

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: Restless Legs Syndrome
Interventions: Rotigotine 1 mg/24 h, Rotigotine 2 mg/24 h, Rotigotine 3 mg/24 h; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Culver City, California

Search by objective public record fields.

SLC6A1-NDD Prospective Longitudinal Natural History Study

A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome